The purpose of this study was to develop a liquid biopsy assay that could determine the methylation status of the BRCA1 promoter to be able to monitor hypermethylation of the BRCA1 promoter and investigate its clinical significance as a predictive biomarker in ovarian cancer patients. Here, BRCA1 is linked to ovarian carcinoma.